# US Biopsy Devices Market

> US Biopsy Devices Market Research Report: Size, Share, Trend Analysis By Product Type (Biopsy Guns, Biopsy Guidance System, Biopsy Needles, Biopsy Forceps, Localization Wires, Others), By Applications (Breast Biopsy, Prostate Biopsy, Liver Biopsy, Lung Biopsy, Gynecological Biopsy, Others), By Guidance (Ultrasound-Guided Biopsy, Stereotactic Guided Biopsy, MRI-Guided Biopsy, CT Guided Biopsy, Others) and By End Users (Hospitals & Clinics, Diagnostic & Imaging Centers, Academic & Research Institutes, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.83%
- **2024:** $ 590.1 Million
- **2025:** $ 624.5 Million
- **2035:** $ 1,100 Million
- **Key Players:** Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (DE), Fujifilm Holdings Corporation (JP), Cardinal Health, Inc. (US)

**Report ID:** MRFR/MED/18046-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biopsy-devices-market-19593

---

## Market Summary

## **US Biopsy Devices Market Overview**

### **Market Size and Growth**

As per MRFR analysis, the US Biopsy Devices Market Size was estimated at 646.8 (USD Million) in 2023. The US Biopsy Devices Market Industry is expected to grow from 688.45 (USD Million) in 2024 to 1,809.23 (USD Million) by 2035. The US Biopsy Devices Market CAGR (growth rate) is expected to be around 9.181% during the forecast period (2025 - 2035).

### **Key US Biopsy Devices Market Trends Highlighted**

The US Biopsy Devices Market is experiencing significant trends driven by technological advancements and a growing population needing diagnostic procedures. Enhanced imaging technologies, including ultrasound, MRI, and CT scans, are improving the precision of biopsy procedures and aiding in the accurate identification of malignant tissues. As the number of cancer cases continues to rise, particularly in the aging population of the US, the demand for these devices is increasing, thus driving market growth. Key market drivers include the increasing incidence of cancer and breast diseases, leading to a heightened focus on early diagnosis and the use of minimally invasive procedures.

The US healthcare system is pivoting towards patient-centered care, which emphasizes rapid and accurate diagnosis with fewer complications, further propelling the adoption of biopsy devices. The rise in research and development activities around biopsy techniques also reflects the ongoing need to innovate in this field. Opportunities in the US market include the expansion of outpatient services and integrating advanced technologies like robotic-assisted biopsy devices, which enhance accuracy and patient comfort. Additionally, the trend towards personalized medicine is creating more demand for precise diagnostic tools, presenting a favorable landscape for new entrants and existing companies to innovate.

Moreover, recent trends in the regulatory landscape, with FDA efforts to streamline the approval process for new biopsy devices and tools, are fostering an environment conducive to market growth. This, combined with rising healthcare expenditures in the US, is leading to more investments in advanced biopsy technologies, solidifying the US as a key player in the global biopsy devices market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Biopsy Devices Market Drivers**

### **Increasing Incidence of Cancer Cases**

The US [Biopsy Devices Market](../../../reports/biopsy-devices-market-2250) Industry is significantly driven by the rising incidence of cancer cases across the nation. According to the American Cancer Society, it is projected that in 2023 alone, approximately 1.9 million new cancer cases will be diagnosed in the United States. This represents a staggering increase over the previous years, suggesting that cancer will continue to be a major health challenge. Given the essential role of biopsy devices in the early diagnosis and treatment of cancer, this trend is expected to propel the demand for such medical devices.

Additionally, organizations like the National Cancer Institute are actively promoting research and development into innovative biopsy techniques, which further supports market growth. The increasing patient population, motivated by heightened awareness and advanced diagnostic technologies, further solidifies the potential of the US Biopsy Devices Market.

### **Technological Advancements in Biopsy Devices**

Technological innovation in biopsy devices is another significant driver for the US Biopsy Devices Market Industry. Recent advancements have led to the development of minimally invasive biopsy techniques, enhancing patient comfort and accuracy in diagnosis. The FDA has recently approved new devices that incorporate robotic assistance and imaging technologies, which improve the precision of biopsy procedures. This increasing adoption of advanced technologies is expected to attract more healthcare providers and patients, consequently boosting market growth.

Institutions such as the Mayo Clinic are actively contributing to the Research and Development of these technologies, promoting higher standards and actualizing more efficient procedures.

### **Growing Awareness and Educational Initiatives**

Heightened awareness regarding the importance of early cancer detection is fueling the US Biopsy Devices Market Industry. Various health organizations, including the Centers for Disease Control and Prevention, have launched several educational initiatives that educate the public about the significance of routine screenings and biopsies. Through campaigns and outreach programs, there is a noticeable uptick in the number of patients opting for these diagnostic procedures.

The emphasis on preventive healthcare is reflected in the increasing participation rates in cancer screening programs, thereby directly impacting the demand for biopsy services. This growing consciousness among the public not only enhances patient outcomes but also underscores the market's prospects for sustained growth.

## **US Biopsy Devices Market Segment Insights**

### **Biopsy Devices Market Product Type Insights**

The US Biopsy Devices Market, focusing on the Product Type segment, reveals a diverse and evolving landscape with several critical components that cater to various clinical needs. Biopsy Guns, recognized for their precision and efficacy, are widely used for obtaining tissue samples and account for a significant portion of the market due to their effectiveness in minimally invasive procedures. Biopsy Guidance Systems enhance the accuracy of biopsies, particularly in complex anatomical areas, and are increasingly adopted to improve patient outcomes and enhance procedural efficiency, which reflects a growing trend towards the integration of advanced imaging technologies within healthcare.

Biopsy Needles, fundamental in tissue sampling, show a steady demand given their essential role across various biopsy methods. These devices are vital for ensuring adequate sample quality and quantity, hence influencing the overall adaptability of biopsy practices in the US healthcare system. Biopsy Forceps, utilized predominantly in gastrointestinal procedures, play an essential role in ensuring targeted biopsies, particularly in diagnosing cancers and other diseases effectively. Localization Wires are pivotal in assisting surgeons during procedures, enhancing the excision of tumors with accuracy, which echoes a broader trend in precision medicine where tailored interventions are prioritized.

The "Others" category encompasses various innovative devices and tools that are emerging within the market, reflecting ongoing advancements and research in biopsy technologies. The market's competitive landscape is further shaped by the increasing incidence of cancer and other chronic diseases in the US, driving demand for reliable and efficient biopsy devices. As these diagnostic tools continue to evolve with technological innovations, the opportunities for improved diagnostics and better patient care in the healthcare industry will expand significantly.

The US Biopsy Devices Market, with its various product types, showcases the industry's responsiveness to the changing healthcare needs, indicating a robust growth potential driven by advancements in medical technology and shifting patient requirements in diagnostic procedures.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Biopsy Devices Market Application Insights**

The Application segment of the US Biopsy Devices Market is witnessing significant evolution driven by advancements in medical technology and increasing cancer prevalence. In particular, Breast Biopsy procedures are essential due to the high incidence of breast cancer in women, making early detection and diagnosis crucial. Prostate Biopsy is equally prominent, especially among older male populations, as prostate cancer remains a leading concern. Liver and Lung Biopsy applications are vital for diagnosing associated malignancies, addressing critical health issues prevalent in the US.

Gynecological Biopsies also play a significant role in women's health, contributing to early detection of various conditions. The segmentation in this market reflects a comprehensive understanding of patient needs and clinical practices, driving innovations aimed at improving diagnostic accuracy and patient outcomes. The US Biopsy Devices Market data indicates a growing focus on minimally invasive procedures, which are generally associated with less recovery time and lower healthcare costs, enhancing patient preferences and market growth.

Overall, as healthcare technologies continue to improve, the significance of each application is expected to increase, underscoring the importance of targeted diagnostics in oncology and other medical fields.

### **Biopsy Devices Market Guidance Insights**

The Guidance segment within the US Biopsy Devices Market plays a crucial role in enhancing the accuracy and efficiency of biopsy procedures, which are vital for cancer diagnosis and monitoring. With an increasing prevalence of cancer in the US, there is an evident demand for advanced diagnostic technologies. Various techniques such as Ultrasound-Guided Biopsy and Stereotactic Guided Biopsy are gaining traction due to their ability to provide real-time imaging, facilitating precise needle placement and minimizing patient discomfort.

MRI-Guided Biopsy is significant as it allows for the visualization of soft tissues, aiding in the diagnosis of tumors that may not be detectable through other means. Furthermore, CT Guided Biopsy remains an important method due to its high-resolution images, enabling targeted sampling of tissues in complex anatomical regions. Each of these guidance techniques addresses unique clinical needs, with their growing adoption driven by technological advancements and an increasing number of outpatient procedures, ultimately contributing to improved patient outcomes in the US Biopsy Devices Market landscape.

With the rapid evolution of imaging technologies, the Guidance segment will continue to advance, providing quality data and enhancing the overall efficacy of biopsy procedures.

### **Biopsy Devices Market End User Insights**

The End User segment of the US Biopsy Devices Market plays a crucial role in shaping the landscape of healthcare diagnostics in the region. Hospitals and clinics serve as primary providers of biopsy procedures, benefiting from advanced technologies and a continuous influx of patients requiring diagnostic services. Diagnostic and imaging centers, on the other hand, are integral to enhancing the accuracy and efficiency of biopsy procedures by utilizing sophisticated imaging techniques, thus improving patient outcomes and reducing the risks associated with invasive procedures.

Academic and research institutes contribute significantly by driving innovation and developing new biopsy devices through extensive research and clinical trials, fostering advancements in this industry. Furthermore, the 'Others' category embodies various healthcare settings that also utilize biopsy devices, ensuring comprehensive patient care across diverse demographics. The growing prevalence of cancer cases and advancements in minimally invasive biopsy techniques fuel the demand across all End User categories, allowing for early detection and better treatment plans, which are essential for improving survival rates in patients.

With the US healthcare system placing a premium on diagnostic accuracy and patient-centered care, the End User segment is positioned to continue its pivotal role in the growth and evolution of the US Biopsy Devices Market.

## **US Biopsy Devices Market Key Players and Competitive Insights**

The US Biopsy Devices Market is characterized by a dynamic competitive landscape marked by innovation, technological advancements, and evolving regulatory standards. Key players are focused on enhancing clinical outcomes through the development of advanced biopsy technologies, such as needle-based, vacuum-assisted, and image-guided biopsy systems, catering to a range of clinical applications from oncology to gastroenterology. As healthcare providers increasingly emphasize minimally invasive procedures, the demand for efficient and precise biopsy devices is on the rise, prompting firms to invest significantly in research and development.

The competitive rivalry is further intensified by mergers and acquisitions, strategic partnerships, and collaborations aimed at expanding product portfolios, enhancing market reach, and streamlining operational efficiencies. This competitive environment requires companies to continuously adapt to market needs while ensuring compliance with safety regulations and addressing the challenges of reimbursement policies.

Exact Sciences stands out in the US Biopsy Devices Market with a strong emphasis on innovative products and services designed to improve cancer detection and diagnosis. The company measures its strengths through a commitment to research and development, leading to the introduction of cutting-edge technologies that enhance precision and reliability in biopsy procedures. Exact Sciences has established a notable presence in the market by aligning its strategic initiatives with the growing demand for less invasive testing and improved patient outcomes.

Through collaborations with healthcare providers and clinical institutions, the company has fortified its reputation and provided a range of solutions tailored to meet specific clinical needs within the US healthcare system. Its approachable platform for obtaining biopsy samples positions it favorably among healthcare professionals aiming for accurate diagnoses, thereby contributing to its competitive edge.

Hologic is recognized for its significant contributions to the US Biopsy Devices Market with a robust array of key products and services that specialize in women's health, particularly in breast biopsy and tissue sampling techniques. The company has developed a diverse portfolio, including advanced vacuum-assisted biopsy systems, which not only enhance procedural efficiency but also aim to improve clinical outcomes. Hologic's strength lies in its extensive market presence and continuous innovation, supported by strategic mergers and acquisitions that have broadened its capabilities and expanded its technological base.

The company's commitment to maintaining high-quality standards and developing comprehensive training programs for healthcare professionals has solidified its positioning in the market. By prioritizing research tailored specifically to the needs of the US healthcare system, Hologic has established itself as a leader in the biopsy devices sector, fostering trust among clinicians and patients alike through reliable and effective diagnostic tools.

### **Key Companies in the US Biopsy Devices Market Include**

## **US Biopsy Devices Market Industry Developments**

The US Biopsy Devices Market has seen significant developments recently, with companies like Exact Sciences and Hologic advancing their research and product offerings. In August 2023, Medtronic announced the launch of a new biopsy device aimed at improving sample accuracy and patient comfort, a move appreciated amidst a growing public focus on minimally invasive procedures. Meanwhile, Abbott Laboratories is making strides in early cancer detection technologies that are poised to revolutionize the market landscape. In September 2023, Boston Scientific expanded its portfolio by acquiring a small oncology-focused firm, which enhances its capabilities within the biopsy device segment.

Growth within the sector has also been bolstered by collaborations among leading entities such as Fujifilm Holdings and Cardinal Health, focusing on integrating digital solutions for more efficient biopsy procedures. Economic factors have driven increased investments in healthcare technologies, which were reflected in the projected growth of the US Biopsy Devices Market valuation, indicating a trend towards greater accessibility and innovation in biopsy solutions over the last few years. The market has continued to evolve with new entries and technological advancements, highlighting its importance in the broader context of healthcare diagnostics in the United States.

## **US Biopsy Devices Market Segmentation Insights**

### **Biopsy Devices Market Product Type Outlook**

### **Biopsy Devices Market Application Outlook**

### **Biopsy Devices Market Guidance Outlook**

### **Biopsy Devices Market End User Outlook**

## Market Drivers

### Growing Geriatric Population

The growing geriatric population in the United States is a significant driver for the biopsy devices market. As individuals age, the risk of developing various health conditions, including cancer, increases. The U.S. Census Bureau projects that by 2030, all baby boomers will be older than 65, leading to a substantial rise in healthcare needs. This demographic shift is likely to result in an increased demand for diagnostic procedures, including biopsies, to manage age-related diseases effectively. Consequently, the biopsy devices market is expected to expand as healthcare systems adapt to cater to the needs of an aging population, ensuring timely and accurate diagnoses through advanced biopsy techniques.

### Rising Healthcare Expenditure

Rising healthcare expenditure in the United States is another critical driver for the biopsy devices market. With healthcare spending projected to reach $6 trillion by 2027, there is a growing emphasis on investing in advanced medical technologies, including biopsy devices. This increase in funding allows healthcare facilities to acquire state-of-the-art equipment and improve diagnostic capabilities. Furthermore, as insurance coverage expands and more patients gain access to healthcare services, the demand for biopsy procedures is likely to rise. The biopsy devices market stands to benefit from this trend, as increased healthcare expenditure facilitates the adoption of innovative biopsy technologies, ultimately enhancing patient care and outcomes.

### Increasing Incidence of Cancer

The rising incidence of cancer in the United States is a primary driver for the biopsy devices market. According to the American Cancer Society, approximately 1.9 million new cancer cases are expected to be diagnosed in 2025. This alarming trend necessitates the use of biopsy devices for accurate diagnosis and treatment planning. As healthcare providers seek to improve patient outcomes, the demand for advanced biopsy techniques is likely to increase. The biopsy devices market is thus positioned to benefit from this growing need, as early detection through biopsies can significantly enhance survival rates. Furthermore, the increasing awareness of cancer screening programs is expected to further propel the market, as more individuals seek diagnostic procedures to identify potential malignancies at an earlier stage.

### Enhanced Awareness and Education

Enhanced awareness and education regarding the importance of early cancer detection are driving the biopsy devices market. Public health campaigns and educational initiatives have significantly increased knowledge about the benefits of regular screenings and biopsies. As individuals become more informed about their health, they are more likely to seek diagnostic procedures, leading to a higher demand for biopsy devices. This trend is particularly evident in high-risk populations, where proactive health management is crucial. The biopsy devices market is thus experiencing growth as healthcare providers respond to this heightened awareness by offering more accessible and advanced biopsy options, ultimately contributing to improved patient outcomes.

### Technological Innovations in Biopsy Devices

Technological innovations are transforming the biopsy devices market, leading to enhanced accuracy and efficiency in diagnostic procedures. Recent advancements include the development of automated biopsy systems and imaging-guided techniques, which improve the precision of tissue sampling. The integration of artificial intelligence in imaging analysis is also gaining traction, potentially increasing the reliability of biopsy results. As a result, healthcare providers are increasingly adopting these advanced technologies, which could lead to a projected market growth of approximately 8% annually over the next five years. The biopsy devices market is thus experiencing a paradigm shift, as these innovations not only streamline the biopsy process but also enhance patient safety and comfort.

## Future Outlook

The [Biopsy Devices Market](https://www.marketresearchfuture.com/reports/biopsy-devices-market-2250) is projected to grow at a 5.83% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures.

**New opportunities:**

- Development of AI-driven diagnostic tools for enhanced accuracy Expansion of telemedicine services for remote biopsy consultations Investment in biodegradable biopsy devices to meet sustainability goals

By 2035, the market is expected to achieve substantial growth, driven by innovation and evolving healthcare needs.

## Segment Insights

### By Product Type: Biopsy Guns (Largest) vs. Biopsy Guidance System (Fastest-Growing)

The US biopsy devices market exhibits diverse segmentation within the product types, with biopsy guns commanding the largest market share owing to their prominent application in various biopsy procedures. Following behind, biopsy needles and biopsy forceps contribute significantly but do not match the widespread use and acceptance of biopsy guns. Biopsy guidance systems, although smaller in share, show promising growth trends as they enhance the precision and effectiveness of biopsy procedures.

Growth trends in the US biopsy devices market are largely driven by the increasing prevalence of cancer and the subsequent demand for accurate diagnostic tools. Innovations in technology, particularly in biopsy guidance systems, are paving the way for their rapid adoption. The drive towards minimally invasive procedures and enhanced patient outcomes are primary factors propelling the acceptance and growth of emerging and established products alike, reshaping the competitive landscape.

Biopsy Guns (Dominant) vs. Biopsy Guidance Systems (Emerging)

Biopsy guns have established themselves as the dominant force in the US biopsy devices market due to their reliability and efficiency in various diagnostic biopsies. They are engineered for precise tissue sampling, catering to a broad range of clinical practices. In contrast, biopsy guidance systems represent the emerging segment, offering advanced imaging technology and navigation capabilities to ensure accurate biopsy execution. This technological advancement addresses the increased demand for accuracy in diagnostics, enabling healthcare providers to improve patient outcomes. Both segments play crucial roles in the market, with biopsy guns leading in traditional applications while guidance systems are gaining traction as essential tools in modern biopsy procedures.

### By Application: Breast Biopsy (Largest) vs. Prostate Biopsy (Fastest-Growing)

In the US biopsy devices market, breast biopsy holds the largest share, reflecting its significance in early cancer detection and diagnosis. Following closely are prostate biopsies, liver biopsies, and lung biopsies, with each segment contributing to the diverse applications of biopsy devices. Gynecological biopsies and others also represent crucial segments, although they hold comparatively smaller market shares. Overall, the distribution showcases a robust segmentation driven by disease prevalence and technological advancements.

Growth trends indicate a steady increase in prostate biopsy devices, driven by rising incidences of prostate cancer and heightened awareness of male health issues. Advancements in imaging technology and needle biopsy techniques enhance the accuracy and safety of these procedures. Breast biopsies will continue to dominate, propelled by ongoing research and innovations that refine diagnostic capabilities. Furthermore, an aging population is expected to drive demand across all segments as the need for early detection increases.

Breast Biopsy (Dominant) vs. Prostate Biopsy (Emerging)

Breast biopsy plays a dominant role in the US biopsy devices market, pivotal for early intervention in breast cancer cases. It benefits from solid clinical guidelines and continuous technological upgrades, making it a preferred choice among healthcare professionals. Its wide acceptance is reflected in the consistent demand for various types of breast biopsy devices, including vacuum-assisted and core needle biopsy tools. Conversely, prostate biopsy, as an emerging segment, is witnessing rapid growth due to the increasing prevalence of prostate cancer and enhanced awareness of men's health. Innovations in transrectal and transperineal biopsy techniques are improving outcomes, contributing to its status as the fastest-growing application. This dynamic creates a competitive landscape, with both segments evolving to meet the changing needs of healthcare providers and patients.

### By Guidance Technique: Ultrasound-guided biopsy (Largest) vs. MRI-guided biopsy (Fastest-Growing)

In the US biopsy devices market, the ultrasound-guided biopsy segment holds the largest market share due to its widespread adoption across various healthcare settings. This technique is favored for its real-time imaging capabilities, allowing for accurate needle placement. Meanwhile, MRI-guided biopsies, while currently smaller in share, are rapidly gaining traction as advancements in imaging technology improve their accessibility and efficacy. 

Growth trends indicate a robust increase in demand for minimally invasive procedures, with healthcare providers increasingly favoring techniques that reduce patient recovery time and enhance diagnostic accuracy. The rising prevalence of cancer and other conditions necessitating biopsies further drives the market. Additionally, innovations in imaging technologies bolster the growth of MRI-guided biopsies, making them a significant focus for future market development.

Ultrasound-guided biopsy (Dominant) vs. MRI-guided biopsy (Emerging)

Ultrasound-guided biopsy remains the dominant technique in the US biopsy devices market, mainly due to its cost-effectiveness and efficiency in various clinical applications. It is especially prevalent in guiding needle insertion for breast, prostate, and thyroid biopsies, relying on real-time ultrasound imaging. In contrast, MRI-guided biopsy is emerging as a key player, particularly in cases where other techniques may fall short, such as in accessing lesions located in difficult-to-reach areas. This method is distinguished by its high-resolution imaging capabilities, which enable precise targeting of tissue for sampling. As adoption grows, particularly in specialized oncology settings, MRI-guided biopsies are anticipated to gain a more significant foothold in the market.

### By End User: Hospitals & Clinics (Largest) vs. Diagnostic & Imaging Centers (Fastest-Growing)

In the US biopsy devices market, hospitals and clinics hold the largest market share, driven by the increasing prevalence of chronic diseases and the rising demand for diagnostic procedures. This segment benefits from advanced healthcare infrastructure and a high patient flow, resulting in significant utilization of biopsy devices. In contrast, diagnostic and imaging centers are experiencing rapid growth as these facilities expand their service offerings and adopt cutting-edge technologies. This growth is particularly fueled by a preference for outpatient procedures and advancements in imaging techniques.

The growth trends for these segments indicate a robust competition and innovation landscape. The hospital and clinic segment's dominance is supported by strong operational capabilities, while diagnostic and imaging centers are emerging as vital players due to their specialized services and technological advancements. Factors such as regulatory support, reimbursement policies, and increasing patient awareness are further driving the traction within both segments.

Hospitals & Clinics (Dominant) vs. Diagnostic & Imaging Centers (Emerging)

The hospitals and clinics segment is characterized by established networks, comprehensive care models, and a diverse patient demographic, which fosters a consistent demand for biopsy procedures. This dominance is underscored by significant investments in infrastructure and training to enhance procedural efficiency. On the other hand, diagnostic and imaging centers are rapidly advancing by incorporating innovative diagnostic tools and specialized services tailored to patient needs. Their agility in adopting new technologies, alongside a growing preference for less invasive procedures among patients, positions them as an emerging force in the market. Together, these segments reflect a dynamic interplay of established and innovative care paradigms that are shaping the landscape of biopsy devices.

## Competitive Benchmarking

The biopsy devices market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Becton Dickinson and Company (US), Hologic, Inc. (US), and Thermo Fisher Scientific Inc. (US) are strategically positioned to leverage innovation and expand their market presence. Becton Dickinson and Company (US) focuses on enhancing its product portfolio through continuous research and development, while Hologic, Inc. (US) emphasizes its commitment to women's health, particularly in breast cancer diagnostics. Thermo Fisher Scientific Inc. (US) appears to be concentrating on integrating advanced technologies into its biopsy solutions, thereby shaping a competitive environment that prioritizes innovation and specialized offerings. In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse offerings, yet the collective influence of major companies like Abbott Laboratories (US) and Siemens Healthineers AG (DE) is significant, as they drive trends and set benchmarks for quality and innovation. In October 2025, Hologic, Inc. (US) announced the launch of a new biopsy device designed to improve accuracy in breast cancer detection. This strategic move is likely to enhance Hologic's competitive edge by addressing the growing demand for precise diagnostic tools. The introduction of this device not only reinforces Hologic's commitment to innovation but also aligns with the increasing focus on early detection and personalized medicine. In September 2025, Thermo Fisher Scientific Inc. (US) expanded its partnership with a leading healthcare provider to enhance the distribution of its biopsy devices across the US. This collaboration is expected to streamline access to advanced diagnostic tools, thereby potentially increasing market penetration. Such partnerships may also facilitate the integration of cutting-edge technologies, further solidifying Thermo Fisher's position in the market. In August 2025, Becton Dickinson and Company (US) completed the acquisition of a smaller biotech firm specializing in biopsy technologies. This acquisition is indicative of Becton Dickinson's strategy to bolster its capabilities in the biopsy segment, allowing for a more comprehensive product offering. The integration of innovative technologies from the acquired firm could enhance Becton Dickinson's competitive positioning and expand its market reach. As of November 2025, current trends in the biopsy devices market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostic processes. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in the evolving market.

## Recent News & Developments

The US Biopsy Devices Market has seen significant developments recently, with companies like Exact Sciences and Hologic advancing their research and product offerings. In August 2023, Medtronic announced the launch of a new biopsy device aimed at improving sample accuracy and patient comfort, a move appreciated amidst a growing public focus on minimally invasive procedures. Meanwhile, Abbott Laboratories is making strides in early cancer detection technologies that are poised to revolutionize the market landscape. In September 2023, Boston Scientific expanded its portfolio by acquiring a small oncology-focused firm, which enhances its capabilities within the biopsy device segment.

Growth within the sector has also been bolstered by collaborations among leading entities such as Fujifilm Holdings and Cardinal Health, focusing on integrating digital solutions for more efficient biopsy procedures. Economic factors have driven increased investments in healthcare technologies, which were reflected in the projected growth of the US Biopsy Devices Market valuation, indicating a trend towards greater accessibility and innovation in biopsy solutions over the last few years. The market has continued to evolve with new entries and technological advancements, highlighting its importance in the broader context of healthcare diagnostics in the United States.

## Report Scope

| MARKET SIZE 2024 | 590.1(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 624.5(USD Million) |
| MARKET SIZE 2035 | 1100.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.83% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (DE), Fujifilm Holdings Corporation (JP), Cardinal Health, Inc. (US) |
| Segments Covered | Product Type, Application, Guidance Technique, End User |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance growth potential in the biopsy devices market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the biopsy devices market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US biopsy devices market?**
A: The market valuation was $590.1 Million in 2024.

**Q: What is the projected market size for the US biopsy devices market by 2035?**
A: The projected valuation for 2035 is $1100.0 Million.

**Q: What is the expected CAGR for the US biopsy devices market during the forecast period 2025 - 2035?**
A: The expected CAGR is 5.83%.

**Q: Which product type segment had the highest valuation in 2024?**
A: Biopsy needles had the highest valuation at $200.0 Million.

**Q: What is the valuation range for biopsy guns in 2024?**
A: The valuation range for biopsy guns was $120.0 Million to $220.0 Million.

**Q: Which application segment is projected to grow the most by 2035?**
A: The prostate biopsy segment is projected to grow significantly, with a valuation range of $130.0 Million to $240.0 Million.

**Q: What is the valuation of ultrasound-guided biopsy in 2024?**
A: Ultrasound-guided biopsy had a valuation of $118.5 Million.

**Q: Which end user segment accounted for the highest market share in 2024?**
A: Hospitals & clinics accounted for the highest market share at $236.04 Million.

**Q: What is the valuation range for diagnostic & imaging centers in 2024?**
A: The valuation range for diagnostic & imaging centers was $177.03 Million to $330.0 Million.

**Q: Who are the key players in the US biopsy devices market?**
A: Key players include Becton Dickinson and Company, Boston Scientific Corporation, and Hologic, Inc.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biopsy-devices-market-19593*